ERBB2 and breast carcinoma: For instance, alpelisib, the only Food and Drug Administration (FDA)‐approved PI3Kα inhibitor for breast cancer, had a mere 4.3% ORR when used as a monotherapy in ER‐positive, HER2‐negative breast cancer patients.19